NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio Inc (NASDAQ:RGNX) released its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.91) by $0.03. The biotechnology company had revenue of $14.70 million for the quarter, compared to analysts' expectations of $7.46 million. Regenxbio had a negative return on equity of 18.74% and a negative net margin of 99.57%. The business's quarterly revenue was up 177.0% on a year-over-year basis. During the same period last year, the firm earned ($0.56) EPS. View Regenxbio's Earnings History.

Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Regenxbio.

6 brokers have issued 1-year target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's stock price to reach $77.50 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View Analyst Price Targets for Regenxbio.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.

News stories about RGNX stock have trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regenxbio earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Regenxbio.

Some companies that are related to Regenxbio include BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Visa (V), Amarin (AMRN), Exelixis (EXEL), Gilead Sciences (GILD), Square (SQ), Alibaba Group (BABA), Immunomedics (IMMU) and Micron Technology (MU).

Regenxbio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.10%), UBS Group AG (1.78%), Credit Suisse AG (1.38%), Kam Lawrence (1.27%), Korea Investment CORP (1.24%) and Goldman Sachs Group Inc. (1.19%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rafferty Asset Management LLC, Bank of New York Mellon Corp, Citigroup Inc., SG Americas Securities LLC, P.A.W. Capital Corp, AQR Capital Management LLC and Franklin Resources Inc.. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

RGNX stock was purchased by a variety of institutional investors in the last quarter, including Kam Lawrence, UBS Group AG, Goldman Sachs Group Inc., Barclays PLC, Parkman Healthcare Partners LLC, Panagora Asset Management Inc., Rhenman & Partners Asset Management AB and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $53.80.

Regenxbio has a market capitalization of $1.98 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.

The official website for Regenxbio is http://www.regenxbio.com/.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]